Table 4.
Clinical characteristics and visual outcomes in patients with UG and OHT-SU according to the type of uveitis.
| Type of uveitis | N | Age at the first episode of uveitis Median (25–75%) | Sex N (F/M ratio): | Final BCVA (logMAR) Median (25–75%)a | Final C/D ratio Median (25–75%)a | Highest IOP Median (IQR 25th and 75th) [Range]a | Abnormal Visual field N (%) | Abnormal OCT N (%) | Mean of hypertensive agents used Median (25–75%)a | Surgically Managed N (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Autoimmune | 26 | 41.0 (24.0–57.0) | (19/7) 2.7:1 | 0.48 (0.09–2.10) | 0.5 (0.3– 0.6) | 22.0 (17.5–29.0) [8–50] | 6 (23.0%) | 7 (26.9%) | 2.0 (1.0–3.0) | 10 (38.4%) |
| Autoinflammatory | 67 | 45.0 (28.5–57.3) | (38/29) 1.3:1 | 0.39 (0.0–1.30) | 0.4 (0.2–0.6) | 23.0 (18.0–31.0) [6–54] | 17 (25.3%) | 21 (31.3%) | 2.0 (1.0–3.0) | 19 (28.3%) |
| Infectious | 37 | 55.5 (42.0–66.7) | (14/23) 0.6:1 | 0.20 (0.0–0.61) | 0.3 (0.2–0.5) | 27.5 (18.2–32.0) [8–62] | 12 (32.4%) | 10 (27.0%) | 3.0 (1.0–3.0) | 10 (27.0%) |
| Mixed | 14 | 48.0 (43.2–55.2) | (8/6) 1.3:1 | 0.04 (0.0–0.20) | 0.5 (0.1–0.8) | 20.5 (15.5–27.5) [9–34] | 3 (21.4%) | 3 (21.4%) | 2.0 (0.0–2.7) | 2 (14.2%) |
| Others | 47 | 57.0 (37.0– 67.0) | (29/16) 1.8:1 | 0.39 (0.09–0.88) | 0.4 (0.2–0.9) | 25.0 (17.7–33.5) [8–56] | 12 (25.5%) | 11 (23.4%) | 3.0 (2.0–3.0) | 16 (34.04%) |
BCVA Best-corrected visual acuity, C/D Cup/Disc, IOP intraocular pressure, OCT optical coherence tomography.
aKruskal–Wallis nonparametric variance analysis test was used to compare continuous variables between groups.